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NEI MISSION/VISION STATEMENT 
 
Congress established the National Eye Institute (NEI) in 1968 with the mission to conduct and 
support research, training, health information dissemination, and other programs with respect to 
blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and 
the special health problems and requirements of the individuals who are visually impaired.  
Inherent in the NEI's mission is the investigation of normal visual processes and health 
information dissemination activities to conduct activities related to the prevention of blindness 
through public and professional education programs and through the encouragement of regular 
eye examinations.  
 
The National Eye Institute will continue to protect and improve the visual health of the Nation 
through the support and performance of the highest quality laboratory and clinical research aimed
at increasing our understanding of the eye and visual system in health and disease and developing 
the most appropriate and effective means of prevention, treatment, and rehabilitation, and 
through the timely dissemination of research findings and information that will promote visual 
health.  
 
OVERVIEW OF THE NEI STRATEGY FOR ADDRESSING HEALTH DISPARITIES 
 
The National Eye Institute’s latest strategic plan, Vision Research-A National Plan: 1999-2003, 
was developed under the auspices of the National Advisory Eye Council.  Over 100 experts from 
all fields of vision research were assembled to make recommendations on research priorities over 
the period covered by the plan.  Among the priorities identified by these experts were several 
related to health disparities.  These priorities included research on glaucoma, diabetic 
retinopathy, myopia, and health services delivery and use.  Recommendations were also made 
regarding training and attracting minority scientists into vision research.  During the review of 
the strategic plan, the draft was sent to over 50 professional, scientific, or advocacy organizations 
that support vision research.  They were asked to consider whether any important areas of 
research or specific issues of importance to vision research had been overlooked.  The final 
document reflects the comments and input received during that process. 
 
For this comprehensive strategic plan and budget to reduce and ultimately eliminate health 
disparities the background, recent progress, and current research were updated.  The areas of 
research priority and research needs and opportunities related to health disparities that were 
identified in the full strategic plan were extracted.  These areas form the core elements for the 
NEI comprehensive strategic plan and budget to reduce and ultimately eliminate health 
disparities.  In addition, the NEI’s National Eye Health Education Program and its activities as a 
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Future strategic plans for reducing health disparities will be integrated into the formal planning 
process the NEI has used over the past 25 years.  However, additional emphasis will be given by 
highlighting health disparities as a specific focus area within the overall institute strategic plan.  
By creating a focus area for reducing health disparities, all research and policy issues can be 
considered together rather than within each programmatic area, thereby facilitating the 
development of recommendations that cut across the formal NEI programs. 
 
 
 Areas of Research Emphasis 
 
  
Glaucoma 
 
Glaucoma is not a single disease but rather a heterogeneous group of disorders that share a 
distinct type of optic nerve damage that can lead to blindness caused by the death of retinal 
ganglion cells.   These diseases involve several tissues in the front and back of the eye.  
Commonly, but not always, glaucoma begins with a defect in the front of the eye.   Fluid in the 
anterior portion of the eye, the aqueous humor, forms a circulatory system that brings nutrients 
and supplies to various tissues.   Aqueous humor enters the anterior chamber via the ciliary body 
epithelium (inflow), flows through the anterior segment bathing the lens, iris, and cornea, and 
then leaves the eye via specialized tissues known as the trabecular meshwork and Schlemm's 
canal to flow into the venous system.   Intraocular pressure is maintained by a balance between 
fluid secretion and fluid outflow.   Almost all glaucomas are associated with defects that interfere 
with aqueous humor outflow and, hence, lead to a rise in intraocular pressure.   The consequence 
of this impairment in outflow and elevation in intraocular pressure is that optic nerve function 
is compromised.   The result is a distinctive optic nerve atrophy, which clinically is characterized 
by excavation and cupping of the optic nerve, indicative of loss of optic nerve axons. 
 
Rationale and Priority 
 
Primary open-angle glaucoma, the most common form of the disease, is characterized by 
relatively high intraocular pressures believed to arise from a blockage of the outflow drainage 
channel or trabecular meshwork in the front of the eye.   However, another form of primary open-
angle glaucoma, normal-tension glaucoma, is characterized by a severe optic neuropathy in the 
absence of abnormally high intraocular pressure.   Patients with normal-tension glaucoma have 
pressures within the normal range, albeit often in the high normal range.  Both these forms of 
primary open-angle glaucoma are considered to be late-onset diseases in that, clinically, the 
disease first presents itself around midlife or later.   However, among African-Americans, the 
disease may begin earlier than middle age.   In contrast, juvenile open-angle glaucoma is a 
primary glaucoma that affects children and young adults.   Clinically, this rare form of glaucoma 
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People 2010  are highlighted.
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Primary open-angle glaucoma can be insidious.  The disease is manifest as a progressive optic 
neuropathy that, if left untreated, leads to blindness.   It usually begins in midlife and progresses 
slowly but relentlessly.  If detected, disease progression can frequently be arrested or slowed with 
medical and surgical treatment.  However, without treatment, the disease can result in absolute 
irreversible blindness.  Even though the initial site is believed to occur in the outflow drainage 
channels at the front of the eye, vision loss from primary open-angle glaucoma is the result of 
damage to the retinal ganglion cells, whose axons form the optic nerve at the back of the eye.
 
 
An estimated 66.8 million people worldwide have glaucoma and nearly 6.7 million will be 
bilaterally blind as a result.1  Glaucoma is a major public health problem in this country, as well. 
It is estimated that as many as 3 million Americans2 have the disease and as many as 120,0003 
blind.  Furthermore, it is the number one cause of blindness in African-Americans.4   
Epidemiological studies conducted in the United States and the West Indies have improved the 
prevalence and incidence estimates of primary open-angle glaucoma among white and black 
populations.   One strength of these studies is the adoption of more inclusive definitions of 
primary open-angle glaucoma that require the presence of visual field loss or optic disc damage, 
but do not necessarily require the presence of elevated intraocular pressure.  The Beaver Dam 
(Wisconsin) Eye Study, which studied nearly 5,000 individuals between the ages of 43 and 84, 
reported a prevalence rate of 2.1 percent in a predominantly Caucasian sample.5   The Baltimore 
Eye Study, with over 5,000 participants age 40 and older, reported a prevalence rate of 1.7 
percent among Caucasian Americans and 5.6 percent among African-Americans.6  The Barbados 
Eye Study, which studied over 4,000 black Barbadians ages 40 to 84, reported a prevalence rate 
of 7 percent7.   The Barbados Eye Study and the Baltimore Eye Study confirm a substantially 
higher prevalence of primary open-angle glaucoma in Caribbean blacks and African-Americans 
than in whites. 
 
Treatments to slow the progression of the disease are available; however, at least half of those 
who have glaucoma are not receiving treatment because they are unaware of their condition8. 
Glaucoma is three to four times as common in blacks as in whites, and blindness from glaucoma 
is six times as common in blacks than in whites.  In its early stages, glaucoma is usually treated 
with drugs in daily eye drops.  In some patients, the beneficial effect of the eye drops lessens with 
time, and “advanced glaucoma” develops.  Recent findings from the NEI-supported Advanced 
Glaucoma Intervention Study suggest that black and white patients with advanced glaucoma 
respond differently to two surgical treatments for the disease.  Although both groups benefit from  
treatment, scientists found that blacks with advanced glaucoma benefit more from a regimen that 
begins with laser surgery, while whites benefit more from one that begins with an operation  
called a trabeculectomy9. 
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glaucoma, because of the large number of people affected and its public health impact. 
forms of glaucoma, the major focus of NEI supported research remains on primary open-angle 
very high intraocular pressure associated with this disease.   Although there are a number of other 
is distinguished from primary open-angle glaucoma not only by its earlier onset but also by the 
are
been isolated and a third has been mapped to chromosome 1.  Three distinct loci associated with 
Reiger’s syndrome, a congenital syndrome that includes glaucoma have been mapped, and one 
of these has been cloned.  Also, the gene for Nail-Patella syndrome, another congenital disorder 
associated with glaucoma, has been cloned.  Other loci mapped include one linked to pigment 
dispersion glaucoma and two for rare forms of adult onset POAG.  Defining roles for these genes 
with respect to glaucoma should indicate pathways that are disrupted and thereby, help increase 
our understanding of the pathology of all forms of glaucoma. 
 
Progress has also been made in the development of new pharmacological agents that might 
protect axons from damage due to glaucoma.  Elevated intraocular pressure is frequently 
associated with glaucoma and explanations for how axons become damaged are usually based on 
the mechanical effects of elevated intraocular pressure.  However, optic nerve damage can occur 
without abnormally high pressures and conversely, elevated pressure does not necessarily lead to 
optic nerve damage.  Discovering the basis of optic nerve degeneration is essential for the 
development of the next generation of glaucoma drugs, neuroprotective agents.  Scientists now 
have evidence that the molecule nitric oxide (NO), is directly involved in mediating the 
degeneration of axons in the optic nerve head10.  Research is being aimed at identifying and 
developing neuroprotective agents as a new class of glaucoma drugs. 
 
An important aim of current research is to develop methods of diagnosis to detect the disease in 
the early stages, when treatment is most effective in minimizing irreversible vision loss.  This is 
made more critical by the apparent absence of symptoms in the early stages of glaucoma.  
Because elevated intraocular pressure is not always accompanied by pathology, nor does elevated  
intraocular pressure always lead to optic neuropathy, the diagnosis of glaucoma now emphasizes 
the presence of visual field loss and observable characteristic optic nerve damage.  Individuals 
with ocular hypertension present a unique dilemma for clinicians.  In the absence of any overt 
pathology, clinicians must decide whether or not to treat these individuals with intraocular 
pressure-lowering medications that can pose a considerable expense and often have side effects.  
This dilemma can be avoided with a more thorough understanding of the natural history of the  
disease and whether early treatment can prevent the onset of glaucoma. 
 
 In its early stages, glaucoma is usually treated with drugs in daily eye drops.  In some patients, 
the beneficial effect of the eye drops lessens with time, and “advanced glaucoma” develops.  
However, the role of topical medications in preventing or delaying sight-threatening damage to 
the eye from glaucoma remains unclear.  In order to evaluate the safety and efficacy of topical 
ocular hypotensive medications in preventing or delaying damage to the optic nerve and loss of 
vision from primary open angle glaucoma, the NEI has funded the Ocular Hypertension 
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In an effort to understand the genetics of susceptibility to open-angle glaucoma, scientists have 
been actively pursuing genes responsible for minor forms of the disease that have clear patterns of 
inheritance.  Presently, ten glaucoma loci have been identified and five of the genes are 
cloned.  A major advance came with the cloning of the gene linked to juvenile glaucoma on 
chromosome 1.  This gene, GLC1A, encodes a protein that is expressed in a tissue involved in 
the maintenance of intraocular pressure.  Two genes for congenital glaucoma syndromes have 
ganglion cell loss occurs and the role played by elevated intraocular pressure in this process.  
Clinical and laboratory research will continue to provide a greater understanding of the normal 
functions of the ocular tissues involved in the disease.  Such studies have already led and will 
continue to lead to the introduction of a variety of new drugs to reduce intraocular pressure, the 
development of new diagnostic tools, better estimates of disease prevalence and incidence, and 
the identification of glaucoma genes. 
 
Objective 
 
Develop improved measures to aid clinical diagnosis of glaucoma; monitor progression of 
disease and treatment effectiveness; and elucidate the pathophysiology and natural history 
of the disease. 
 
Action Plan  
 
Improve our understanding of the nature and course of glaucoma, incorporating studies 
of comorbidity, natural history, and genetics, with special emphasis on Hispanic, Native 
American, and African-American populations. 
 
Results from the Baltimore Eye Study, the Beaver Dam Eye Study, and the Barbados Eye 
Study have firmly established race as a significant risk factor for primary open-angle 
glaucoma.  Though there is variation in estimates that reflects the different populations 
studied, all of these studies confirm a substantially higher prevalence of primary open-
angle glaucoma in blacks.  Furthermore, the rates for blindness due to primary open-angle 
glaucoma in African-Americans are six times higher than the rates for the Caucasian 
population, reflecting not only an increased rate of the disease but also more severe 
disease.  Other ethnic and racial groups have been studied less rigorously.  There is a 
dearth of information about the prevalence and incidence of glaucoma in Hispanic and 
Native American populations; therefore, studies need to be initiated in these populations 
to obtain this critical information. 
 
Questions of comorbidity have not been adequately resolved.  Studies that sought to 
investigate the relationship between glaucoma and myopia have yielded ambiguous 
results.  There is also incomplete and equivocal epidemiologic information available on  
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Because characteristic visual field changes in glaucoma patients are due to degeneration of retinal 
ganglion cells, clinical progress goes hand-in-hand with progress in understanding how retinal 
Treatment Study (OHTS).  The OHTS is designed to determine the potential benefit of treatment 
with ocular hypotensive medications in preventing or delaying damage to the eye from glaucoma.  
Additionally, the high percentage of African Americans participating will also ensure adequate 
evaluation of the effectiveness of topical medication in treating African Americans with 
glaucoma as the study progresses toward conclusion in the coming years.11 
progression of glaucoma is unknown.  Questions remain concerning whether or not a 
compromised vascular system contributes to glaucomatous pathology.  The difficulty of 
measuring ocular blood flow hampers progress in understanding its impact on the 
survival of retinal neurons and visual function. 
 
The large number of gaps in knowledge about the nature and course of glaucoma point to 
the need for rigorous epidemiologic studies.  Well-designed studies that use 
systematically selected sample sizes (from census tract data, for example) have high rates 
of participation by the study sample, and use standard procedures for assessing disease 
and measuring risk factors needed to address these issues.  There is also a critical need for 
better population-based screening procedures that are simple, inexpensive, portable, and  
effective.  Developing such methods will be useful for testing populations that historically 
have limited access to formal healthcare systems, for determining more accurately the 
incidence and prevalence of glaucoma in epidemiologic studies, and for screening large 
populations in remote regions of the world.   
 
It is anticipated that significant progress will be made in the next five years to improve 
our understanding of the nature and course of glaucoma, incorporating studies of 
comorbidity, natural history, and genetics, with special emphasis on Hispanic, Native 
American, and African-American populations.  
 
Performance Measures 
 
The NIH has developed a set of performance measures as a part of its Government 
Performance and Review Act (GPRA) assessment plan for its research program. The NIH 
has concluded that strictly numeric goals and measures are neither feasible nor sufficient 
to capture the breadth and impact of NIH’s research program.  Therefore, as provisioned 
for in GRPA, the NIH has defined research performance goals that rely on criteria that 
are more nearly descriptive in nature [“alternative form” assessment, Sec. 1115 (b)(1)].  
These performance measures are:  add to the body of knowledge about normal and 
abnormal biological functions; develop new or improved instruments and technologies 
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Risk factors for glaucoma need to be identified and verified.  The question of whether 
there are susceptibility genes that can affect the course of the disease, especially in regard 
to ethnic and racial differences, is being actively pursued.  With advances in genetics, 
environmental effects also need to be understood so that researchers can better determine 
the interaction of genetics and environment in the natural history of this disease.  
Currently, important known risk factors for glaucoma include elevated intraocular 
pressure, advanced age, optic disc abnormalities, and family history of primary open-
angle glaucoma.  However, the contribution each of these known risk factors to the 
of comorbidity is highlighted by the fact that the rate of hypertension is high in minority 
populations. 
the relationship between glaucoma and vascular disease.  The need to resolve the question 
Myopia 
 
Myopia, or nearsightedness, is a common condition in which images of distant objects are 
focused in front of, instead of on, the retina, usually because the eye is too long.  More than 30 
years ago, scientists found that raising a variety of animals with a closed eyelid led to the 
development of myopia, because the eye became elongated.  Similar observations were made in 
human infants in which trauma or some other disorder resulted in neonatal eyelid closure.  Over 
the next three decades a clearer picture of some of the processes involved in the control of 
refractive error in growing eyes has emerged. 
 
Rationale and Priority
 
 
Myopia occurs in approximately 25 percent of the population of the United States.12  Myopia is 
an important public health problem, which entails substantial societal and personal costs.  It is 
highly prevalent in our society and even more frequent in Asian countries; furthermore, its 
prevalence may be increasing over time.  The most common form of myopia is childhood 
myopia, which begins after age 6 and progresses rapidly until age 16.  Myopia progression results 
from excessive growth of the eye, primarily by enlargement of the vitreous chamber.  Excessive 
elongation of the eye is a major risk factor for retinal detachment.  A clinical study of myopia in 
first and second generation Hispanic, white, Asian, and black immigrant students in this country 
demonstrated that Asian immigrants have a significantly higher prevalence of myopia.
Increased prevalence of myopia among Alaskan Eskimos and some American Indian Tribes has 
also been reported.14, 15 
 
High myopia contributes to significant loss of vision and blindness.  At present, the mechanisms 
involved in the etiology of myopia are unclear, and there is no way to prevent the condition.  
Current methods of correction require lifelong use of lenses or surgical treatment, which is 
expensive and may lead to complications. 
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Outcomes Measures   
 
The NEI will support research that will build on the knowledge gained from its 
investment in the highest quality science and translate the findings of this research 
program to develop new treatments and diagnosis for glaucoma 
 
 
 
 
for use in research and medicine; develop new or improved approaches for preventing or 
delaying the onset of disease and disability; develop new or improved methods for 
diagnosing disease and disability; and, develop new or improved approaches for treating 
disease and disability.  The NEI will continue to support the very best and highest quality 
research identified through the peer-review process. 
After extensive argument about whether to attribute myopia to visual factors or genetic factors, 
13 
Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study.  It is a multi-center, 
observational investigation of ocular development and refractive error development in 
schoolchildren.  It adds three clinical centers to the Orinda Longitudinal Study of Myopia 
(OLSM), begun in 1989, specifically to describe normal ocular growth in children ages 6 to 14 
years, and to develop the ability to predict juvenile onset myopia before it is clinically evident.  
In addition to the more than 1,300 predominantly Caucasian children enrolled in the OLSM, 
three additional clinical sites enroll African-American, Hispanic, and Asian children.  The 
children are examined annually for at least four years. 
 
Another ongoing study is the Correction of Myopia Evaluation Trial (COMET), a multicenter, 
randomized, double-masked clinical trial designed to evaluate whether progressive addition 
lenses slow the progression of juvenile-onset myopia as compared with single vision lenses.  The 
primary outcome of the study is progression of myopia, defined as the magnitude of the change 
relative to baseline in spherical equivalent refraction, determined by cycloplegic autorefraction.  
The secondary outcome of the study is axial length measured by A-scan ultrasonography. 
In a similar study being conducted in Oklahoma, the hypothesis that correction with bifocal 
spectacle lenses rather than single-vision lenses will slow the progression of myopia in children 
with near-point esophoria will be tested.  The primary outcome variable is refraction as measured 
with an automated refractor.  Axial length is measured with ultrasound in order to test the  
corollary hypothesis that use of bifocals will slow ocular growth in these myopic children.  We   
will also examine the amount of close work performed by subjects and the degree of parental 
myopia as factors that may influence myopia progression.  
Objective  
Determine the etiology of human myopia and identify the risk factors associated with this 
and other refractive errors so as to prevent their occurrence or progression. 
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The NEI is currently conducting a number of studies designed to provide more information on 
the development and prevention or treatment of myopia.  One such study is the Collaborative 
experimentation on animals in the past two decades has provided a clearer, but as yet incomplete, 
picture of some of the processes involved in the control of refractive error in growing eyes.  Two 
insights are especially important.  First, images not focused on the retina guide the developing 
eye to correct for this defocus.  Thus, animals with either hyperopia (farsightedness) or myopia 
imposed by spectacle lenses alter the shape of their eyes to bring the images back into focus.  
Second, changes in focus of images on the retina can cause changes in eye growth directly by a 
cascade of chemical signals from the retina to the sclera.  Thus, in animals, normal refractive 
development and myopia of moderate severity may involve a visual feedback mechanism that 
controls eye growth.  Recent evidence that this feedback occurs in primates suggests that these 
discoveries have substantial practical implications for the clinical treatment of myopia and other 
refractive disorders in humans, affording opportunities for testing this hypothesis in clinical 
trials. 
   
As knowledge of the underlying mechanisms that control eye growth and refractive 
compensation increases, the ability to assess the risk factors that predict the development 
of myopia in children or adults has increased as well.  Reading is the most established 
risk factor for myopia.  More recent observations have strengthened the association of the 
amount of near work with the rate of myopic progression. 
 
Because the sharpness of the image during reading depends on the precision of 
accommodation, it is significant that myopic children have poorer accommodation than 
others.  Additional research is needed into how accommodation and convergence are 
related to myopia.  Researchers have also long suspected that genetic factors play a role in 
the cause of myopia.  The evidence is especially strong in the case of pathological myopia 
(myopia of high degree).  Refractive errors of monozygotic twins are more closely 
aligned than they are for dizygotic twins.  A greater prevalence of myopia exists among 
the children of myopic parents than among the children of nonmyopic parents.  Recent   
studies of the eye in infancy have also shown that the seeds of myopia may appear early 
in development.  Longitudinal studies of refractive error have suggested that some 
myopic children may have previously been myopic as infants. 
   
To make the transition from animal studies to clinical studies, there is a pressing need to 
determine how similar the biological mechanisms of eye growth are in different species, 
and how similar experimental models of myopia (by visual deprivation or the imposition 
of hyperopia by spectacle lenses) are to the myopia that develops in schoolchildren.  
Enough is presently known to begin to evaluate promising treatments for preventing the 
onset or slowing the progression of myopia and systematically investigate the risk factors 
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Action Plan 
 
Identify the visual error signals that govern eye growth during correction for refractive 
error. And, identify human risk factors for myopia and abnormal eye growth and 
evaluate promising treatments for preventing the onset of or slowing the progression of 
myopia, such as special spectacles, contact lenses or pharmacological treatments. 
 
In animal models, it is now accepted that visual circumstances can influence refractive 
error, and that this influence involves modification of the growth of the eye.  Thus, a 
feedback mechanism is at work in ocular growth--visual input influences growth, which 
in turn modifies the visual input.  Importantly, the influence of vision on growth can be 
communicated directly from the retina to the sclera without involvement of the brain.  
This view of the mechanisms of refractive adjustments has provoked a search for the 
visual cues the retina uses to discern whether to accelerate or retard the axial growth of 
the eye and for the signals, presumably chemical, by which the retina communicates to 
the sclera the appropriate direction of growth.  The most provocative candidates are 
dopamine and acetylcholine because agonists and antagonists, respectively, reduce form-
deprivation myopia in both birds and primates. 
 It is anticipated that significant progress will be made in the next five years to identify the visual error signals that govern eye growth during correction for refractive error. And, 
identify human risk factors for myopia and abnormal eye growth and evaluate promising 
treatments for preventing the onset of or slowing the progression of myopia, such as 
special spectacles, contact lenses or pharmacological treatments.   
Performance Measures 
 
The NIH has developed a set of performance measures as a part of its Government 
Performance and Review Act (GPRA) assessment plan for its research program. The NIH 
has concluded that strictly numeric goals and measures are neither feasible nor sufficient 
to capture the breadth and impact of NIH’s research program.  Therefore, as provisioned 
for in GRPA, the NIH has defined research performance goals that rely on criteria that are
    more nearly descriptive in nature [“alternative form” assessment, Sec. 1115 (b)(1)].  
    These performance measures are: add to the body of knowledge about normal and 
    abnormal biological functions; develop new or improved instrument and technologies for 
    use in research and medicine; develop new or improved approaches for preventing or 
    delaying the onset of disease and disability; develop new or improved methods for 
    diagnosing disease and disability; and, develop new or improved approaches for treating 
    disease and disability.  The NEI will continue to support the very best and highest quality 
    research on myopia identified through the peer-review process. 
 
                    Outcomes Measures   
 
                    The NEI will support research that will build on the knowledge gained from its 
                    investment in the highest quality science and translate the findings of this research 
                    program to develop new treatments and preventive strategies for myopia. 
                                    
                  
                                Health Services Research 
 
                                To understand the impact of eye disease and visual impairment on the Nation's health, data are 
                                needed on the number and characteristics of people with various eye conditions, the effects of 
                                these conditions on quality of life, and the economic burden of these conditions.  This 
                                information will serve to increase public awareness of the personal and societal costs of visual 
                                impairment and be useful to those who are interested in allocating adequate resources to 
                                Americans most in need of visioncare services. 
 
                            Rationale and Priority
 
 
To                       To advance understanding of these issues, the National Eye Institute (NEI) devoted a section to
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associated with the development of myopia.
health services research in its strategic plan, Vision Research-A National Plan:  1999-2003.  The 
NEI defines the field of health services research broadly to include such diverse topics as: 
increasing patient access to and utilization of visioncare services, improving the delivery of 
vision services by eyecare professionals, and measuring the visual health of patients receiving 
eyecare services.  Various studies have demonstrated the need to ensure patient access and 
utilization of visioncare services particularly where treatments are available to improve or 
preserve vision.  In blacks undertreatment has been reported for cataract, diabetic retinopathy, 
and glaucoma.16, 17, 18, 19 
 
A number of different scientific methodologies are used in conducting health services research 
projects.  These include but are not limited to: clinical outcomes research of new or existing data 
survey research techniques, translational research methods, decision and utility analytic methods, 
health economics, traditional epidemiologic methods, and randomized clinical trials.  The 
selection of design methodology should be scientifically justified as appropriate for the research 
objectives of a given study. 
 
Quality-of-life assessments have been incorporated into the design of several NEI-funded 
epidemiologic studies and clinical trials, therein recognizing that a patient's quality of life is an 
important facet to consider in assessing visual health.  In response to the need to more completely
understand the impact of clinical interventions specifically on vision-related quality of life from a 
patient perspective, the NEI fostered the development and testing of a questionnaire, the NEI-
Visual Functioning Questionnaire (NEI-VFQ), to collect this important information. 
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Findings from recent studies have shown that the majority of people having cataract extraction 
surgery subsequently report substantial improvement in their ability to see and to perform 
common, necessary, daily activities. 
 
Numerous studies have reported that a large number of people who have diabetes do not obtain 
an annual dilated eye examination. Currently funded projects are attempting to identify specific 
reasons why the medical system is failing to reach this population at increased risk of visual 
impairment. Other studies are testing specific interventions geared toward the patient or the 
eyecare provider to increase the rates of ophthalmic screening among people with diabetes. 
 
The NEI is currently supporting the Ophthalmic Complications Prevention Trial designed to 
evaluate the efficacy of an inexpensive educational intervention to promote annual ophthalmic 
screening among low-income Black women with diabetes.  
 
Another study entitled Why Preventable Blindness Occurs in Diabetes is attempting to learn why 
the current health care system is unsuccessful in preventing blindness from diabetic retinopathy, 
a disease for which effective treatment is available. 
 
The NEI is also supporting a study to develop, implement, and evaluate a comprehensive culture-
 
specific and community-based education program for the prevention of eye disease in diabetic  
 Oklahoma Indians. 
 
The Diabetic Retinopathy Awareness program is seeking to control visual loss from diabetic 
retinopathy in the community by evaluating various methods of increasing the use of 
ophthalmology services among people with diabetes. 
 
The NEI is supporting a major research project in Los Angeles County, California, the Los 
Angeles Latino Eye Study, to gain a greater understanding of the prevalence and incidence of eye 
disease among Latinos.  Researchers are conducting in-depth  interviews with study participants 
on their medical and ophthalmic histories, use of medications, tobacco and alcohol consumption, 
and utilization of health care services.  Because so little is known about the visual health needs of 
this segment of the population, the data collected from this study will be instrumental in 
determining the prevalence of cataract, glaucoma, age-related macular degeneration, and diabetic 
retinopathy among Latinos in this community.  The study will also determine the proportion of 
blindness and visual impairment that is caused by these diseases, and will explore the association 
of various risk factors, such as smoking or sun exposure with ocular disease.  The study will also 
examine the effect of eye disease and disorders on quality of life and will assess the cost/benefit 
of eye care services and the utilization of those services in the Los Angeles Latino community.  
Continuation of this study should yield results that will assist in setting eye and vision health 
services priorities in the Los Angeles area and the rest of the country. 
 
Another study supported by the NEI that is designed to improve our understanding of eye disease 
and visual impairment in the Hispanic population in this country is the Visual Impairment 
Among Hispanics in Arizona Study.  This study is collecting data to determine the prevalence of 
diabetic retinopathy, cataract, and other causes of blindness and visual impairment in 4,500 
Mexican Americans age 40 and older residing in Arizona.  The results will provide new 
information of visual impairment and blindness in the Mexican-American community. 
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Objective 
 
Assess the impact of eye disease and visual impairment on the Nation’s health and 
determine the most appropriate use of diagnostic strategies and treatments scientifically 
demonstrated to improve vision and preserve sight. 
 
Action Plan 
  
Determine the number of Americans with eye disease and visual impairment and measure 
the impact on medical costs and costs to society associated with these conditions.  
Identify the factors associated with the most effective delivery and use of visioncare 
services. 
 
Basic information on the visual health of the U.S. population is critical for increasing 
public awareness of the effects and costs of visual impairment, assessing the need for 
eyecare services, evaluating the delivery of vision care, and setting priorities for vision 
research.  However, gathering detailed ophthalmic data on a large, nationally 
representative sample, while scientifically preferred, is not practical.  Over the past 
decade, studies on three large ethnically and geographically different populations have 
generated information on the prevalence of and risk factors associated with eye disease 
and vision loss.  Long-term followup of these groups of Caucasians and African-
Americans is providing additional information on the frequency of new cases of eye 
disease.  Similar information is needed on children and minority populations of all ages, 
particularly Hispanics and East Asians. 
 
Even with better estimates of the numbers of Americans with eye disease and visual 
impairment, complete estimates of the economic and social costs of these conditions are 
lacking.  Previous economic analyses of the costs associated with eye conditions have 
generally been limited to consideration of direct medical costs to the patient or third-party 
payers, and to indirect costs to society in the form of tax deductions or disability 
payments.  Given that the onset of visual loss can be gradual and can worsen over time, 
the true costs of visual impairment are difficult to estimate.  The magnitude of direct and 
indirect medical costs, as well as the costs to society, depends on a number of factors, 
including: the nature and severity of the visual impairment; the nature and severity of 
other illnesses; a patient's age, socioeconomic status, and family setting; cultural 
expectations regarding self-reliance and independence; attitudes about health and health 
care; and the part of the country where the person lives. All of these factors need to be 
considered in subsequent research efforts.  Also of importance are costs associated with 
changes required in the home or workplace that allow visually impaired persons to safely 
go about their daily activities and income lost by family members who may have to 
reduce their hours of gainful employment or quit their job to care for a family member 
who has a visual deficit.  
 
 
 13 
Since there are both genetic and environmental determinants of eye disease, it is 
particularly important to study ethnically diverse populations. Additional epidemiologic 
studies on Hispanic, East Asian, and Native American populations are needed to provide 
regional estimates of disease and to identify risk factors, quality-of-life considerations, 
and access to care issues, which may differ by ethnic group. National estimates of disease 
burden among Caucasians and African-Americans may be more readily available using 
methods like mathematical modeling techniques to extrapolate these data from rates of 
disease found in NEI-funded, community-based studies.
 
Given the increasing number of Americans covered by managed care plans, research to 
examine the delivery and utilization of vision care takes on even greater importance.  
Little is known about the quantity and quality of eyecare services offered to different 
segments of the American population, or how the changing patterns of delivering 
visioncare services influence a person's access to and utilization of appropriate, high-
quality vision care.  With a characterization of the eyecare services offered by providers   
 in different health systems, it may be possible to design and test specific interventions to 
improve the delivery and utilization of vision care and thereby reduce rates of blindness 
and visual impairment. 
 
The movement toward fully automated medical records may provide a cost-efficient 
opportunity to study patterns of care across a variety of healthcare delivery settings.  
Automated systems may be especially useful for monitoring changes in the content, cost, 
and use of visioncare services.  It is important to note, however, that persons in systems 
of care with automated records may be different from the general population. 
 
The NEI anticipates that significant progress will be made in the next five years to 
determine the number of Americans with eye disease and visual impairment and measure 
the impact on medical costs and costs to society associated with these conditions. And, 
that the factors associated with the most effective delivery and use of visioncare services 
will be identified.  
 
Performance Measures 
 
The NIH has developed a set of performance measures as a part of its Government 
Performance and Review Act (GPRA) assessment plan for its research program. The NIH 
has concluded that strictly numeric goals and measures are neither feasible nor sufficient 
to capture the breadth and impact of NIH’s research program.  Therefore, as provisioned 
for in GRPA, the NIH has defined research performance goals that rely on criteria that are 
more nearly descriptive in nature [“alternative form” assessment, Sec. 1115 (b)(1)].  
These performance measures are: add to the body of knowledge about normal and 
abnormal biological functions; develop new or improved instrument and technologies for 
use in research and medicine; develop new or improved approaches for preventing or 
delaying the onset of disease and disability; develop new or improved methods for 
diagnosing disease and disability; and, develop new or improved approaches for treating 
disease and disability.  The NEI will continue to support the very best and highest quality 
health services research identified through the peer-review process. 
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Outcomes Measures   
 
The NEI will support health services research that will build on the knowledge gained 
from its investment in the highest quality science and translate the findings of this 
research program to improve health services. 
 
 
Diabetic Retinopathy
Diabetes mellitus is one of the leading causes of death in this country and throughout the world
 but is also a major cause of blindness.  One of the ocular complications of diabetes is diabetic
retinopathy.  Diabetic retinopathy causes excessive vascular permeability and is typically 
accompanied by neovascularization with ballooning of the retinal capillaries to form 
microaneurysms.  The blood-retinal barrier may break down within these microaneurysms, 
causing leakage of blood proteins with subsequent hemorrhage into the retina and visual loss.  
Newly formed blood vessels tend to break through the retinal surface, which may result in 
hemorrhage into the vitreous and in traction retinal detachment, where the retina is pulled away 
from the underlying choroid.  Because of the prevalence of diabetes, diabetic retinopathy is a 
major cause of blindness.  
 
Rationale and Priority 
 
The Centers for Disease Control and Prevention estimate that there are nearly 16 million 
Americans with diabetes, but that only 10 million have been diagnosed.  Almost 800,000 new 
cases are diagnosed annually.  Although the incidence of insulin-dependent diabetes mellitus 
(IDDM) in whites is nearly twice the incidence in blacks, the prevalence of non-insulin-
dependent diabetes mellitus (NIDDM) is between 1.4 and 2.3 times higher in blacks than in 
whites.  Similarly the prevalence of NIDDM is two to three times higher in Hispanics than in 
non-Hispanic whites.  Generally, NIDDM is more common in African Americans, Mexican 
Americans, Japanese Americans, and Native Americans than in non-Hispanic whites.20  The 
prevalence of the disease in U.S. Hispanics varies by geographic location and education.21,22 
 
With the increased prevalence of NIDDM in Mexican Americans, studies have shown that there 
is also a significantly increased risk of severe retinopathy.23  Diabetic retinopathy has also been 
shown to occur more often in blacks than in whites, but this difference was not explained by 
differences in risk factors alone.  Rather, the results suggested that the differences may be due to 
a greater susceptibility to the adverse effects of hyperglycemia and/or blood pressure.24   Although 
this may help explain the increased prevalence and severity of diabetic retinopathy in blacks, it 
does not explain the excess prevalence and disease severity in Mexican Americans with 
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education efforts.    Although currently recommended treatments are over 95 percent effective in
preventing further vision loss, about half of those who could benefit from treatment being
treated.
Vascular endothelial growth factor (VEGF) has become a leading candidate for the long-sought
  
  
 
  
NIDDM.    Previous studies have demonstrated that disease duration, increased hyperglycemia,
diagnosis at an earlier age, and the need for insulin treatment is associated with increased
association was found was found with socioeconomic status.     The finding that a high
prevalence of diabetic retinopathy in both Mexican Americans and Caucasians.  Interestingly, no
percentage of blacks and Hispanics have severe diabetic retinopathy at initial presentation for
treatment, strongly argues for earlier referral from primary care physicians and increased public
agent responsible for neovascularization in retinal diseases.  Retinal neovascularization is often
associated with retinal ischemia and hypoxia.  Hypoxia induces VEGF production.  VEGF is
present at high concentrations in the vitreous fluid of patients with proliferative diabetic
retinopathy and is low to absent in the vitreous of patients with nonvasoproliferative disease.
25
27
26 
VEGF levels are high in the retina and vitreous of animals with experimental retinal or iris 
neovascularization, and methods that block VEGF action (e.g., neutralizing antibodies, soluble 
receptors, or antisense DNA) prevent neovascularization.  In human eyes with retinal and 
choroidal vascular diseases, and in experimental animals, VEGF is localized primarily in the glial 
cells of the retina and optic nerve, and in the RPE cells.  Although hypoxia has not been 
identified in choroidal neovascular diseases, VEGF has been reported in the RPE cells of 
choroidal neovascular membranes.  While macular edema and neovascularization apparently 
result when VEGF is upregulated during certain pathologic processes, the normal function of 
VEGF may be to stimulate blood vessel growth in fetal development.  Mice with a targeted 
disruption of the VEGF gene die in embryo due to defective vascular development. 
 
Another growth factor that has been shown promise in the control of angiogenesis is pigment 
epithelium-derived growth factor (PEDF), a protein found in the healthy eye.  PEDF is secreted 
by the retinal pigment epithelial cells that underlie and nourish the neural retina.  Recently, a 
team of scientists demonstrated that PEDF can transiently delay the death of photoreceptors in 
mouse models of inherited retinal degenerations.  This protein has also been shown to promote 
neurite-outgrowth and protect spinal cord motor neurons against natural and induced death using 
cell culture and animal model systems.  Another group of scientists has shown that PEDF can 
prevent the growth of endothelial cells that form new blood vessels.  Thus, PEDF behaves as a 
potent neurotrophic factor for the retina and nerves of the central nervous system, as well as a 
potent inhibitor of angiogenesis.  Continued research to learn how PEDF works may provide 
information that will contribute to the development of effective treatments for several neural 
degenerative and angiogenic diseases, such as retinitis pigmentosa, macular degeneration, and 
diabetic retinopathy.28, 29 
 
Another new therapeutic agent has been developed that may be important in treating blindness in 
humans caused by diabetic retinopathy or macular degeneration.  The new drug, called PKC 412, 
can be taken orally and appears to have several actions on growth factors and their receptors 
within the retina.  While PKC 412 blocks new abnormal vessel growth, it has no apparent 
adverse effects on normal, fully mature vessels.  Additional research is needed to determine 
whether PKC 412 is a viable therapeutic alternative in the treatment of diabetic retinopathy.30 
 
In diabetic retinopathy, glucose may exert its deleterious effects by directly modifying the 
expression of genes.  Cultured retinal pericytes grown in high glucose show differences in gene 
expression when compared to cells grown in normal glucose.  Basement membranes of blood 
vessels from diabetic or galactosemic animals contain a profile of collagens different than 
basement membranes of control animals, suggesting altered expression of genes.  Similarly, 
when animals in poor diabetic "control" or those maintained on high galactose diets for a short 
time are switched to "tight" control or a normal diet, they develop retinopathy after a delay of 
several years.  The Diabetes Control and Complications Trial and its followup showed that the 
delay of onset and possible prevention of diabetic eye disease was due to tight control of 
glycemic levels.  This study has made a significant contribution to patient welfare and quality of 
life. 
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A role for pituitary-associated factor in diabetic retinopathy has been appreciated for many years. 
Several decades ago, retinal neovascularization was found to regress after pituitary ablation in 
diabetic patients that appeared to be related to postsurgical growth hormone (GH) deficiency.  In 
addition, insulin-like growth factor-1 (IGF-1) appears to be associated with proliferative 
retinopathy.  To study the role of GH and IGF-1 in ischemia-induced retinal neovascularization 
and its interaction with VEGF, transgenic mice were studied.  It was found that systemic 
inhibition of GH, IGF-1, or both may have therapeutic potential in preventing some forms of 
retinopathy. 
 
Current research efforts continue to focus on the development of improved pharmacologic agents 
that will  prevent or cause the regression of retinal or choroidal neovascularization.  Studies are 
continuing to determine the role of tissue hypoxia in VEGF upregulation and expression.  The 
role of oxidation products in the pathogenesis of retinal vascular diseases is also being studied, as 
well as the role of antioxidants that may be used therapeutically to retard this pathogenesis. 
 
In spite of the finding that laser therapy has been highly successful in preventing vision loss from 
proliferative diabetic retinopathy, it has been estimated that up to 50 percent of patients that 
could benefit from treatment are not receiving appropriate treatment.  This suggests that current 
public and professional education efforts are essential to preserving the vision of diabetic 
patients. 
 
Objectives 
 
Understand the pathogenesis of diabetic retinopathy and other vascular diseases of the 
retina and develop strategies for primary prevention and improved treatment. 
 
Action Plan 
 
Investigate the pathogenesis of vascular diseases of the retina and choroid, including 
diabetic retinopathy; develop better methods of prevention and therapy. 
 
Recent advances have provided the identification and characterization of factors and 
proteins that may play a critical role in the management of diabetic retinopathy.  There is 
a need to test new therapeutic approaches with potentially useful agents such as VEGF 
neutralizing agents, inhibitors of isoform of protein kinase C (PKC), aminoguanidine, and 
            inhibitors of aldose reductase.  Collaborations between National Institutes of Health 
            investigators and the private sector should be encouraged.  Since neuron and glial cells in 
            the retina are primary sources of vasoactive compounds such as VEGF, it will be 
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important to understand the metabolism of these cells in diabetes.  To increase the pace of 
            discovery of genetic factors involved in diabetic retinopathy, both molecular techniques 
            and animals models need to be developed to allow study of genetic factors involved in the 
            disease.  It is important to identify key genes and as well as the mechanisms involved in 
            hyperglycemia.  Chronic hyperglycemia is the hallmark event for the development and 
 The NEI anticipates that significant progress will be made in the next five years to 
understand the pathogenesis of vascular diseases of the retina and choroid, including 
diabetic retinopathy; and develop better methods of prevention and therapy. 
 
Performance Measures
 
 
The NIH has developed a set of performance measures as a part of its Government 
Performance and Review Act (GPRA) assessment plan for its research program. The NIH 
has concluded that strictly numeric goals and measures are neither feasible nor sufficient 
to capture the breadth and impact of NIH’s research program.  Therefore, as provisioned 
for in GRPA, the NIH has defined research performance goals that rely on criteria that are 
more nearly descriptive in nature [“alternative form” assessment, Sec. 1115 (b)(1)].  
These performance measures are: add to the body of knowledge about normal and 
abnormal biological functions; develop new or improved instrument and technologies for 
use in research and medicine; develop new or improved approaches for preventing or 
delaying the onset of disease and disability; develop new or improved methods for 
diagnosing disease and disability; and, develop new or improved approaches for treating 
disease and disability.  The NEI will continue to support the very best and highest quality 
research on diabetic eye disease identified through the peer-review process. 
 
Outcomes Measures
   
 
The NEI will support research that will build on the knowledge gained from its 
investment in the highest quality science on diabetic retinopathy and translate the findings 
of this research program to improved treatments and prevention strategies for the ocular 
complications associated with diabetes. 
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progression of the disease, and hyperglycemia can act through its effect on genetically 
 
   
 
 
  
  
   
 
  
controlled mechanisms.  The blood-retinal barrier is often compromised in the diabetic
state; therefore, it is important to undertake molecular studies of the embryonic
development of the blood-retinal barrier, the molecular mechanisms of its maintenance in
adult life, and its breakdown in diseased states.  Since oxidative processes may be
involved in diabetic retinopathy, the measurement of toxic oxidation products in tissues
and evaluation of antioxidant enzymes by direct enzyme assay of small tissue samples are
needed.  The preventive effects of antioxidant compounds on lesions putatively caused by
toxic oxidation products need to be tested in experimental animals or in human clinical
trials.
Training of Minority Scientists
The strategies of developing a well-trained pool of laboratory and clinical scientists for the future
must include the achievement of scientific literacy through innovative science education
 
 
 
programs at the elementary level through high school for all students regardless of age or gender 
or cultural, racial, or ethnic background.  The NEI must take full advantage of the changes in the 
demographic patterns of the workforce and make special efforts to foster the scientific careers of 
women and minority groups, who will make up the majority of new workers by the year 2000. 
Programs of support for specific training in visual sciences at graduate and postgraduate levels 
must convince students that their educational endeavors will be rewarded with opportunities for 
productive careers and research support.  Therefore, the NEI's emphasis on individual 
investigator-initiated research project grants must continue to be given high priority. 
 
Objective 
 
Ensure the proper resource requirements through Training/Career Development. 
 
Action Plan 
 
Continue to attract strong minority scientists into vision research using the NIH-wide 
program for research supplements for underrepresented minorities. 
 
New vision researchers must come in greater measure from members of ethnic minority 
groups.  Members of minorities are markedly underrepresented in science in this country 
and, therefore, are an increasingly important source of talent for maintaining leadership in 
this area.  Since the National Advisory Eye Council’s (NAEC) last major planning effort, 
lack of marked success to increase the numbers of underrepresented minorities in  
biomedical science, including vision research, clearly makes the case for the need for new 
strategies.  The NEI has enthusiastically participated in NIH-wide special programs for 
underrepresented minorities.  The Council reaffirms its recognition that progress in this 
area can come only if potential laboratory and clinical scientists seek and obtain sufficient 
grounding in fundamental levels of biological, physical, and mathematical sciences.  This 
means that programs must begin at the elementary school and junior high school levels.  
The vision community must become involved in vision science programs at local schools, 
sharing the excitement and enthusiasm of science.  Vision research organizations may be 
able to assist with these outreach programs nationwide.  A school program called 
"Vision," for children in grades 4 through 8, was developed by the NEI in cooperation 
with The Association for Research in Vision and Ophthalmology.  This program is a 
series of three lessons that was designed for vision researchers and eyecare professionals 
for school classroom visits. 
 
Performance Measure 
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The NEI will monitor the number of supplements that are awarded each year to support 
underrepresented minorities who are pursuing careers in eye and vision research.
 
 
The NEI will build on successful strategies that recruited underrepresented minorities into 
basic and clinical eye and vision research.   
 
 
Minority Representation in Clinical Trials  
The NEI and NAEC fully endorse and support the NIH Guidelines on the Inclusion of Women 
and Minorities as Subjects in Clinical Research.  Because the primary aim of research is to 
provide scientific evidence leading to a change in health policy or a standard of care, it is 
imperative to determine whether the intervention or therapy being studied affects women or men 
or members of minority groups and their subpopulations differently.  To this end, the NIH 
guidelines are intended to ensure that all future NIH-supported biomedical and behavioral 
research involving human subjects will be carried out in a manner sufficient to elicit information 
about individuals of both genders and the diverse racial and ethnic groups and, in the case of 
clinical trials, to examine differential effects on such groups.  Increased attention, therefore, must 
be given to gender, race, and ethnicity in earlier stages of research to allow for informed 
decisions at the Phase III clinical trial stage.  The guidelines reaffirm NIH's commitment to the 
fundamental principles of inclusion of women and racial and ethnic minority groups and their 
subpopulations in research.  This policy will continue to provide a variety of new research 
opportunities to address significant gaps in knowledge about health problems that affect women 
and racial/ethnic minorities and their subpopulations.  
The guidelines require that when a Phase III clinical trial is proposed, evidence must be reviewed 
to show whether or not clinically important gender or race/ethnicity differences in the 
intervention effect are to be expected. This evidence may include, but is not limited to, data 
derived from prior animal studies, clinical observations, metabolic studies, genetic studies, 
pharmacology studies, and observational, natural history, epidemiology and other relevant 
studies.  
Objective  
Continue to ensure that all clinical trials that are funded by the NEI adhere to the NIH 
Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research.  
Action Plan  
Ensure that all clinical trials funded by the NEI adhere to the NIH Guidelines on the 
inclusion of Women and Minorities as Subjects in Clinical Research.  This will be an 
ongoing effort that will continue throughout the period of this plan and not incur any 
significant costs.  
 
 20 
 
 
Outcomes Measure
The NEI will closely monitor all clinical trials and applications to assure that appropriate 
numbers of women and  minorities are included. 
 
Outcome Measures 
 
The NEI will strongly enforce the tenants of the NIH Guidelines on the inclusion of 
women and minorities, and the NEI will communicate to clinical research applicants the 
need to include women and minorities in their clinical protocols.    
 
National Eye Health Education Program 
 
In 1989, the National Eye Institute (NEI) launched the National Eye Health Education Program 
(NEHEP), with the goal of increasing awareness among health care professionals and the public 
of scientifically based health information that can be applied to preserving sight and preventing 
blindness.  Numerous organizations (more than 50 in all) from both the public and private sectors 
joined in partnership with the NEHEP.  Working together, these partners attempted to reach 
select target audiences, informing them of the importance of early detection and treatment of eye 
diseases, particularly glaucoma and diabetic retinopathy, and persuading them to make an 
appropriate change in behavior.  The NEHEP currently has three major ongoing 
education/outreach programs.  
 
Objective 
 
Continue to increase awareness among health care professionals and the public of scientifically 
based health information that can be applied to preserving sight and preventing blindness. 
 
Action Plan 
 
Participants in the NEHEP Planning conference recommended two target audiences for 
this Program:  people with diabetes and health care professionals.  They also 
recommended that messages be directed to family members and other groups, including 
educators and clergy.  Subsequent phases of the Program included groups in which 
diabetes is more prevalent than in the general population, including Native Americans, 
Hispanics, and African Americans.  The NEHEP has developed the Educating People 
with Diabetes Kit for health professionals and Ojo con su Visión (Watch Out for Your 
Vision), a Spanish-language booklet, designed to educate Hispanics with diabetes about 
the ocular complications of the disease.  
 
Participants in the NEHEP Planning Conference identified three target audiences for 
glaucoma education:  glaucoma patients, the general public, and health care professionals. 
The current general primary target groups are Blacks over age 40 and anyone over age 60.  
It also will be important to reach eye and other health care-related professionals to help 
motivate the at-risk populations to have regular eye exams.  Educating the general public 
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Performance Measures
 
  In late 1999, the NEHEP launched a new program for the purpose of addressing the 
impact of low vision on those who have it and to bring the message to them, their 
families, and the health and service professionals who care for them that information and 
help are available.  The two primary audiences are (1) people age 65 and older who have 
decreased visual function that interferes with their activities of daily living and (2) people 
under age 65 who are particularly at risk for low vision--i.e., Hispanic/Latino and African 
American populations.  NEHEP is an ongoing activity of the NEI that will continue on to 
2006 and beyond.  
 
Performance Measures 
 
The NEHEP partnership will pretest the materials that it plans to distribute with focus 
groups to determine the effectiveness of the materials used to communicate NEHEP’s 
message to its target populations.  An analysis of public queries to the NEI Office of 
Health Education, Communication, and Public Liaison will also be conducted to 
determine if the products that NEHEP produces are having a positive impact on the 
public’s knowledge of eye health. 
 
Outcome Measures 
 
The NEHEP partnership will make changes based on the results of its evaluation of the 
program to ensure that the program continues to be effective in communicating to the 
public information about eye health and eye disease. 
 
 
Healthy People 2010: Vision and Hearing Chapter 
 
Healthy People 2010 represents the ideas and expertise of a diverse range of individuals and 
organizations concerned about the Nation’s health.  The Healthy People Consortium-an alliance 
of more than 350 national organizations and 250 State public health, mental health, substance 
abuse, and environmental agencies-conducted three national meetings on the development of 
Healthy People 2010.  Members of the voluntary, scientific, and professional organizations that 
comprise the vision research community joined forces to recommend the inclusion of a section 
on the visual health needs of the Nation.  The NEI agreed to serve as a co-lead agency and 
support the inclusion of a chapter on vision.  Both vision and hearing were selected to share the 
lead of a new chapter on Vision and Hearing in Healthy People 2010.  A workgroup has already 
been formed and the initial focus of the group is to develop the necessary data sources to assess 
progress in accomplishing the program’s objectives. 
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is a means to ensuring long-term success. The Glaucoma Public Education Program 
 
 
emphasizing early detection.
conduct glaucoma awareness activities and comprehensive public service campaigns
consists of a Glaucoma Community Education Kit that community agencies can use to
 
Action Plan 
 
Increase the proportion of persons who have a dilated exam at appropriate intervals. 
Increase the proportion of preschool children aged 5 years and under who receive vision 
screening.  Reduce uncorrected visual impairment due to refractive errors.  Reduce 
blindness and visual impairment in children aged 17 and under.  Reduce visual 
impairment due to diabetic retinopathy.  Reduce visual impairment due to glaucoma.  
Reduce visual impairment due to cataract.  Reduce occupational eye injury.  Increase the 
use of appropriate personal protective eyewear in recreational activities and hazardous 
situations around the home.  Increase the use of vision rehabilitation services and 
adaptive devices by people with visual impairments. 
 
Healthy People 2010 is a ten-year plan to improve the health of the American people. 
 
Performance Measures 
 
A mid-course evaluation will be performed in 2005 to assess of the progress that has been 
made toward achieving the goals set forth in Healthy People 2010. 
 
Outcome Measures 
 
Based on the results of the mid-course review, strategies for achieving the goals of 
Healthy People 2010 will be adjusted to enhance the probability of achieving those goals 
by 2010. 
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Increase quality and years of healthy life and eliminate health disparities. 
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   NEI Health Disparities Budget   
   (Dollars in Millions)   
        
       
FY 2002 FY 2003 
Institute / Center Research Infrastructure Outreach Research Infrastructure Outreach 
NEI $35.30 $3.90 $2.30 $38.30 $4.20 $2.50 
 
 
 
